News & Updates
Filter by Specialty:
Imatinib may reduce mortality in hospitalized COVID-19 patients
The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.
Imatinib may reduce mortality in hospitalized COVID-19 patients
06 Jun 2022
Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.
Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022
Step-down therapy may be the better strategy for certain COPD patients
Switching from triple therapy to dual bronchodilation improves symptom control in patients with chronic obstructive pulmonary disease (COPD) in a new analysis of the DACCORD study.
Step-down therapy may be the better strategy for certain COPD patients
03 Jun 2022
HRT use tied to reduced COVID-19 death risk
The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.
HRT use tied to reduced COVID-19 death risk
02 Jun 2022
INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD
Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).
INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD
31 May 2022
MS patients on certain DMTs may have limited protection from COVID-19 vax
The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.